SUMOylation modulates the stability and function of PI3K-p110β
- 8 April 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cellular and Molecular Life Sciences
- Vol. 78 (8), 4053-4065
- https://doi.org/10.1007/s00018-021-03826-6
Abstract
Class I PI3K are heterodimers composed of a p85 regulatory subunit and a p110 catalytic subunit involved in multiple cellular functions. Recently, the catalytic subunit p110β has emerged as a class I PI3K isoform playing a major role in tumorigenesis. Understanding its regulation is crucial for the control of the PI3K pathway in p110β-driven cancers. Here we sought to evaluate the putative regulation of p110β by SUMO. Our data show that p110β can be modified by SUMO1 and SUMO2 in vitro, in transfected cells and under completely endogenous conditions, supporting the physiological relevance of p110β SUMOylation. We identify lysine residue 952, located at the activation loop of p110β, as essential for SUMOylation. SUMOylation of p110β stabilizes the protein increasing its activation of AKT which promotes cell growth and oncogenic transformation. Finally, we show that the regulatory subunit p85β counteracts the conjugation of SUMO to p110β. In summary, our data reveal that SUMO is a novel p110β interacting partner with a positive effect on the activation of the PI3K pathway.Keywords
Funding Information
- Ministerio de Ciencia, Innovación y Universidades (BFU-2017-88880-P, RTI2018-095818-B-100)
- Consellería de Cultura, Educación e Ordenación Universitaria, Xunta de Galicia (ED431G 2019/02, ED481A-2018/110, ED481A-2020/160)
This publication has 38 references indexed in Scilit:
- Sumoylation: A Regulatory Protein Modification in Health and DiseaseAnnual Review of Biochemistry, 2013
- Novel approaches to inhibitor design for the p110β phosphoinositide 3-kinaseTrends in Pharmacological Sciences, 2013
- Regulation of the tumor suppressor PTEN by SUMOCell Death & Disease, 2012
- SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membraneNature Communications, 2012
- Structure of Lipid Kinase p110β/p85β Elucidates an Unusual SH2-Domain-Mediated Inhibitory MechanismMolecular Cell, 2011
- PI3K pathway alterations in cancer: variations on a themeOncogene, 2008
- Class I PI3K in oncogenic cellular transformationOncogene, 2008
- PTEN-deficient cancers depend on PIK3CBProceedings of the National Academy of Sciences of the United States of America, 2008
- Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimersProceedings of the National Academy of Sciences of the United States of America, 2007
- SH2 domains recognize specific phosphopeptide sequencesCell, 1993